Quest Diagnostics adds Los Angeles lab network to its stable

Quest Diagnostics sign
In taking over some of CLA's assets, Quest will add several patient service centers to its network in southern California. (Ed Uthman/CC BY-SA 2.0)

Quest Diagnostics has acquired certain assets of California Laboratory Associates (CLA), a clinical lab network in the greater Los Angeles area, for an undisclosed sum.

With the acquisition, Quest will add several CLA patient service centers to its network, expanding its reach in southern California.

"This acquisition will deepen our presence and ability to serve the region, while advancing our strategy to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions,” said Quest CEO Steve Rusckowski in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Quest Diagnostics rolls out more accurate, nonfasting cholesterol tests

Caregivers and the lab at Providence St. Joseph Medical Center in Burbank previously supported CLA’s operations and patients. While Quest is taking over some of CLA’s assets, Providence St. Joseph will continue to run its lab for hospital patients and certain outside physician services, according to the statement.

"Providence caregivers who have supported CLA's operations and patients have provided exemplary service across the greater Los Angeles area, helping to care for patients and coordinating with provider offices to ensure quality laboratory services," said Erik Wexler, CEO of Providence St. Joseph Health, Southern California Region. "We are confident Quest Diagnostics will carry on the high standards our caregivers set in providing quality and compassionate care."

In July, Quest picked up a pair of Texas laboratory businesses and set up a national “center for excellence” for cancer precision diagnostics, strengthening its presence in the southwestern U.S.

“This transaction will not only accelerate Quest's growth in cancer diagnostics, but also holds the promise of improving care for patients with cancer in Texas and the entire United States,” Rusckowski said at the time.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.